Form 4: Phio Pharmaceuticals CEO Buys 5,000 Shares

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of common stock.

Summary

• Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp. (PHIO), acquired 5,000 shares of the company's common stock.
• The transaction took place on December 23, 2025, at a price of $1.02 per share.
• Following this purchase, Mr. Bitterman directly holds 286,421 shares of Phio Pharmaceuticals common stock, which includes shares underlying unvested restricted stock units.

Sentiment

Score: 7

Explanation: An insider purchase by the CEO typically indicates management's confidence in the company's future performance and valuation, which is generally viewed positively by the market.

Positives

• The Chairman, President, and CEO, Robert J. Bitterman, purchased 5,000 shares of company common stock, signaling confidence in the company's future prospects.
• The purchase was made at $1.02 per share, representing a direct investment by a key executive.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing reports a past transaction and does not provide forward-looking statements or guidance.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This filing reports an individual insider transaction and does not provide data for comparison to industry benchmarks or competitor results.

Related Party Transactions

• This filing details an insider stock purchase, which is a form of related party transaction. It does not disclose other related party dealings beyond this direct equity acquisition.

Stakeholder Impact

• Shareholders may interpret the CEO's purchase as a positive signal, potentially increasing confidence in the company's stock.
• Employees might view the CEO's investment as a sign of stability and belief in the company's direction.

Next Steps

• No future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The direct purchase of company stock by the Chairman, President, and CEO, Robert J. Bitterman, signals strong insider confidence in Phio Pharmaceuticals Corp.'s future prospects and current valuation. Such an action by a key executive is often interpreted by the market as a bullish indicator, suggesting that management believes the stock is undervalued or poised for growth. This direct investment aligns the CEO's interests more closely with those of shareholders, making it a positive signal for potential investors.

Keywords

Phio Pharmaceuticals, PHIO, Insider Trading, Stock Purchase, CEO, Form 4, Beneficial Ownership, Robert J. Bitterman, Equity Acquisition